Literature DB >> 11579646

Use of topical ketanserin for the treatment of ulcers in leprosy patients.

J J Salazar1, G G Serrano, G I Leon-Quintero, B M Torres-Mendoza.   

Abstract

A comparative study was carried out in which 66 leprosy patients with ulcers were randomly divided in two groups of 33 patients each: Group A (experimental group) was treated with ketanserin gel (2%) and group B with clioquinol cream and/or Lassar paste during a three month period. At the end of the study, when ulcer sizes in the two groups were compared, the group treated with topical ketanserin showed superior results (p < 0.001 using Kolmogorov-Smirnov's test). We conclude that the drug is useful as coadjuavant treatment for healing ulcers in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579646

Source DB:  PubMed          Journal:  Indian J Lepr        ISSN: 0254-9395


  4 in total

1.  The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Authors:  Q Tang; Z-Q Li; W Li; J Guo; H-Y Sun; X-H Zhang; C-P Lau; H-F Tse; S Zhang; G-R Li
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

Review 2.  WITHDRAWN: Interventions for skin changes caused by nerve damage in leprosy.

Authors:  Liv Merete Reinar; Louise Forsetlund; Arild Bjørndal; Diana Nj Lockwood
Journal:  Cochrane Database Syst Rev       Date:  2019-08-01

Review 3.  Interventions for ulceration and other skin changes caused by nerve damage in leprosy.

Authors:  Liv Merete Reinar; Louise Forsetlund; Linda Faye Lehman; Kjetil G Brurberg
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 4.  Cost-effectiveness of interventions to prevent disability in leprosy: a systematic review.

Authors:  Natasja H J van Veen; Paul McNamee; Jan Hendrik Richardus; W Cairns S Smith
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.